Exact Sciences Corp., a Madison company aiming to bring a DNA-based colon cancer screening test to market, said it raised $64.7 million in a public stock offering. The amount was $8.5 million more than expected because firms underwriting the offering bought additional shares, said Maneesh K. Arora, Exact Science's chief financial officer.